Health Integrator

Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.

RaySearch is advancing cancer treatment through pioneering software that driving force for innovation in oncology.

Adsorbi is engaged in the development of an innovative biomaterial using cellulose as its foundation.

At Corsmed we develop one of the world’s most proficient MRI (Magnetic Resonance Imaging) simulation platforms. Often referenced as “the flight simulator of MRI”, our platform is used to educate current and future MR-operators to better help patients all around the world. https://corsmed.com/

Acorai is working on a non-invasive device called the Acorai Heart Monitor, designed to manage heart failure by monitoring intracardiac pressure. This device aims to decrease the need for hospitalizations and readmissions. It employs machine learning to analyze data from acoustics, vibrations, and waveforms to accurately measure intracardiac pressures. Our technology is precise, carries minimal clinical and regulatory risks, does not heavily rely on reimbursement, and can be expedited for commercial availability.

Monivent is a young medtech startup based in Gothenburg, Sweden. Monivent aim to increase patient safety for newborn babies requiring help to start breathing at birth. 3-6% of all newborns require manual ventilation at birth, when air is manually forced down the baby’s lungs using different manual ventilation equipment. Sub‐optimal treatment, using too little or too much air, may cause brain damage or chronic lung injury. Yet there are no good tools available to ensure that an effective but still gentle treatment is given. Monivent Neo100 is a non-invasive monitoring device measuring the airflow given to the baby. Instant feedback throughout the ventilation enables the caregiver to make simple adjustments to ensure a better treatment within recommended guidelines. Monivent Neo100 is an add-on to existing manual ventilation equipment and comprises sharp technical solutions, simple interfaces and wireless data transfer for maximum ease of use and minimal impact on current practices. Monivent guides and supports the caregiver during manual ventilation of newborns to ensure a safe and gentle resuscitation with reduced risk of injury.

Enzymatica is a life science company that specializes in providing effective solutions for common diseases caused by viruses or bacteria. In a short amount of time, they have created a unique oral spray for colds called ColdZyme® which has become a top-selling product in Swedish pharmacies. They also develop medical devices for upper respiratory infections, oral health, and veterinary products. Enzymatica is based in Lund, Sweden and is publicly traded on Nasdaq First North.

MucoLife Therapeutics is revolutionizing the treatment of Chronic Obstructive Pulmonary Disorder (COPD) by developing innovative mucolytic medications that focus on reducing mucus buildup in the airways.

It's hard to find your best-fit therapist. It shouldn't be. Meela matches people to their best-fit therapist and therapy method powered by a research-based matching algorithm taking into account personal preferences, psychological needs, and symptoms. Meela's solution is 25 times more effective than other providers in matching clients with a therapist they click with, and as a result return to consistently and get better. Operating in Sweden and the UK, with over 450 psychotherapists and psychologists in Sweden and over 150 therapists in the London area.

Tandem Health is focused on delivering healthcare services, while Tandem enables users to easily document medical information soon after patient appointments. Tandem Health develops technologies that streamline healthcare administration.

Newbury Pharmaceuticals is developing a range of exclusive and licensed products with the goal of becoming a top generic pharmaceutical company.

We have developed a microsystem based technology that offers a solution for near-patient blood sampling e.g. at home. Patients can themselves conveniently leave blood samples (as dried blod spots) and send it by mail to a laboratory for analysis. This is possible through our new disposable sampling chip that can meter and store an exact blood volume which allows for quantitative measurements, something that so far not has been possible. This is of particular importance for patients requiring continuous therapeutic drug monitoring. Our technology will reduce the need to travel and healthcare resources spent on taking blood samples. We address a major growing market where only in Sweden more than a million therapeutic drug monitoring samples are taken each year.